trending Market Intelligence /marketintelligence/en/news-insights/trending/qqqe4kbj9ngipfyfdes84q2 content esgSubNav
In This List

Roche ends development for spinal muscular atrophy treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roche ends development for spinal muscular atrophy treatment

Roche Holding AG said it decided to stop developing neuromuscular drug olesoxime due to continued difficulties with the treatment.

"Despite all of our efforts and a strong desire to deliver olesoxime as a medicine to people with SMA, we have concluded that this is not going to be possible," a news release from the Swiss drugmaker's F. Hoffmann-La Roche Ltd. unit stated.

The company said it will identify and provide alternative treatment options to patients enrolled in its ongoing study of olesoxime, called Oleos. Roche noted that the most recent analysis of trial data showed a worsening in symptoms, contributing to its decision to stop development.

Olesoxime is an investigational molecule meant to treat spinal muscular atrophy, or SMA, a rare genetic disorder characterized by loss of voluntary muscle function. Roche acquired olesoxime when it acquired France-based Trophos SA in 2015.

Roche said it is developing another SMA treatment, RG7916, with PTC Therapeutics Inc.